Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke (EAST)
Stroke
About this trial
This is an interventional treatment trial for Stroke focused on measuring Free Radical Scavenger, Selective Thrombin Inhibitor, Acute ischemic stroke (nonlacunar and noncardioembolic)
Eligibility Criteria
Inclusion Criteria: Acute ischemic stroke < 24 hours of onset Measurable neurological deficits caused by the present attack, ranging from 1 to 22 of NIHSS score on admission Exclusion Criteria: Definite or possible cardiogenic brain infarction Definite lacunar infarction Prior ischemic stroke within 6 months Evidence of hemorrhagic brain infarction, epidural hematoma, intracerebral hematoma, or intraventricular hemorrhage Severe consciousness disturbances (semicoma to deep coma) Neurological signs clearing spontaneously Disability of 2 or more on mRS score before the index stroke aPTT being out of the normal range or 1.5 times longer than the pretreatment value If taking an oral anticoagulant, INR being 1.6 or more, or no INR data Treatment with urokinase, t-PA, heparin, ozagrel sodium, warfarin, or antiplatelet except for aspirin before enrollment Intravascular surgery, surgical operation, hyperbaric oxygen therapy, or hypothermia therapy before enrollment Serum creatinine >1.5 mg/dL Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc. Neoplasm Pregnancy Hypersensitivity to test drugs
Sites / Locations
- EAST Study Office c/o National Cardiovascular Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
A
B
The patients who are allocated to Argatroban monotherapy
The patients who are allocated to Edaravone-Argatroban combination therapy